Chief Scientific Officer
CurrentDeveloping novel biologics to target and eliminate key drivers of cancer recurrence and metastasis.
Sep 2023 - Present
AeroLeads people directory · profile
Seng-Lai "Thomas" Tan, Ph.D. Email & Phone Number
Drug Hunter/Developer, Biotech Executive and Chief Scientific Officer
at
TFC Therapeutics
LinkedIn matched
✓ Verified Jun 2026
3 data sources
Profile completeness 100%
Current company
Role
Drug Hunter/Developer, Biotech Executive and Chief Scientific Officer
Location
Cambridge, Massachusetts, United States
Who is Seng-Lai "Thomas" Tan, Ph.D.? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Seng-Lai "Thomas" Tan, Ph.D. is listed as Drug Hunter/Developer, Biotech Executive and Chief Scientific Officer at TFC Therapeutics, based in Cambridge, Massachusetts, United States. AeroLeads shows a matched LinkedIn profile for Seng-Lai "Thomas" Tan, Ph.D..
Seng-Lai "Thomas" Tan, Ph.D. previously worked as Chief Scientific Officer at Tfc Therapeutics and Associate Editor at Frontiers In Immunology. Seng-Lai "Thomas" Tan, Ph.D. holds Ph.D., Microbiology (Immunology) from University Of Washington - School Of Medicine.
Company email context
Email format at TFC Therapeutics
This section adds company-level context without repeating Seng-Lai "Thomas" Tan, Ph.D.'s masked contact details.
TFC Therapeutics
Review company-level records connected to Seng-Lai "Thomas" Tan, Ph.D. before choosing the right outreach path.
Profile bio
About Seng-Lai "Thomas" Tan, Ph.D.
Executive member capable of formulating & executing discovery & translational biology strategy across functional & interdisciplinary groups at both small biotech & large biopharmaceutical companies.Experienced drug hunter/developer in different therapeutic areas: infectious disease, autoimmunity, oncology, and immuno-oncology, and across various modalities, including monoclonal & multi-specific antibodies, immunocytokines, antibody drug conjugates, & cell-penetrating stapled peptidesTrack record in developing biologics & small-molecule modalities targeting TGFbeta, TCR, TLR/interferon pathways, IL-6, TL1A, common gamma chain pathways, Th17 differentiation, & PKC-SYK-BTK signaling axis Well versed in various aspects of assembling preclinical data package, including pharmacologic evaluation of compounds, identification of biomarkers and patient stratification strategies, to support clinical development candidates and enable INDs. Extensive experience in investor & biopharma presentations to support fundraising efforts, and evaluation of in-licensing opportunities (technologies, early & late-stage assets) in partnership with Business Development.Vast experience in managing collaborative relationships & strategic alliances with a wide network of industry & academic connections, as well as service sectors.Strong record in delivering project milestones and mentoring junior project leaders and senior scientists. Enjoy setting goals, career development and performance appraisals as well as building and nurturing a strong talent pool. Visible and well-connected in the immunology and oncology research community; Active in scientific journal and patent publications, & oral presentations at scientific meetings.
Listed skills include Drug Discovery, Immunology, Drug Development, Biomarkers, and 41 others.
Current workplace
Seng-Lai "Thomas" Tan, Ph.D.'s current company
Company context helps verify the profile and gives searchers a useful next step.
15 roles
Seng-Lai "Thomas" Tan, Ph.D. work experience
A career timeline built from the work history available for this profile.
Associate Editor
Current
Frontiers In Immunology
Overseeing & managing the peer-review process of submitted manuscriptsContributing to the strategic direction of the section by helping to expand the editorial reviewer board & co-editing and nominating a high-profile Research Topic around an influential scientific theme
Jul 2023 - Present
Senior Scientific Advisor
Current
Aug 2021 - Present
Chief Scientific Officer
Led the scientific strategy of Bicara’s platform & pipeline products to support clinical development & identify new product opportunitiesManaged an R&D team of 65 scientists & overseeing scientific operations to ensure the organization meets its scientific & product development objectives Represented Bicara alongside the CEO & other members of the.
May 2020 - Aug 2021
Consultant
Self-Employed
Advising clients on translational studies to support IND & clinical studiesAnswering diligence questions to support newco formation & reverse mergers
May 2023 - Aug 2023
Chief Scientific Officer
Led all aspects of the immuno-oncology therapeutics discovery & early development process by leveraging the Immunitas single-cell genomics, computational biology & antibody discovery platformProvided support & guidance for IND-enabling activities for IMT-009, lead asset targeting CD161 for cancer immunotherapyBuilt out expertise in antibody discovery &.
Aug 2021 - May 2023
Scientific Consultant
Advised client on the early development of MCT1/4 dual inhibitor in immunology & immuno-oncology, leading to successful series ALiaised with CROs in implementation & execution of such projects
Jul 2017 - Jun 2021
Vice President, Head Of Immunology
Elstar Therapeutics Inc.
Devised and implemented effective strategies to build a portfolio of differentiated and high value projects in immuno-oncologyDefined staffing, equipment and external collaboration needs to build state-of-the art in vitro/in vivo pharmacological and translational science capabilities; currently managing a team of 15 scientistsProvided scientific leadership.
Jun 2017 - May 2020
Senior Director, Head Of Immunology
Responsible for formulating and executing discovery and translational biology strategy for FORMA projects in immuno-oncology and inflammatory / autoimmune disease, while expanding capabilities in interrogating rationale immuno-oncology combinationsAccountable for delivery of the pre-clinical pipeline, support of the clinical pipeline and direct input into.
May 2015 - Jun 2017
Director, Head Of Cellular And Translational Immunology
Developed cellular assays using primary human cells derived from healthy donors and patient cohorts to support the discovery of NCE and NBE as well as their non-clinical evaluationAdvanced mechanistic understanding and thus proof of confidence of novel therapeutic agents for autoimmune diseaseLed a cross-departmental ‘task force’ aimed to promote.
May 2013 - May 2015
Interim Consultant
Following the Nutley site closure, I was recruited to provide scientific and strategic consulting to Roche Actemra (anti-IL-6R antibody) Global Medical Affairs. I advised clients in the biopharma industry on early research and development projects. My task is to coordinate with CROs in implementation and execution of several projects. I was involved in.
Feb 2013 - Jun 2013
Associate Director
Performed planning for the drug discovery group, including reviewing and selecting portfolio projects, identifying in-licensing opportunities, and providing input on department budget and lab safety issues Involved in preparing Investigator’s Brochure and other related documents for IND submission and presentations to Scientific Advisory Board as well as.
Oct 2010 - Feb 2013
Principal Scientist
Managed several projects simultaneously, including small-molecules targeting tumor cell inflammation and apoptosis as well as antibody drug conjugate (ADC) programs, through collaborations with several functional groups, including Lead Discovery, Bioinformatics, Protein Sciences and Structural BiologyData mining analysis of genetic profiling data of.
Sep 2006 - Oct 2010
Senior Scientist/Research Scientist/Senior Research Scientist
Led discovery efforts to the program sanction of pre-clinical candidates for cancer therapyProposed and served a project leader of the PKC-theta inhibitor program for immune tolerance therapy (multiple sclerosis and rheumatoid arthritis); demonstrated a critical role for PKC-theta in regulation of IL-17A productionProvided scientific expertise to.
Sep 2000 - Sep 2006
Adjunct Assistant Professor
Liaison to Lilly Biology Academics Contacts CommitteeIdentified critical collaborations/interactions with academic researchersMember of PhD Advisory CommitteesGuest lecturer
May 2001 - May 2005
2 education records
Seng-Lai "Thomas" Tan, Ph.D. education
Ph.D., Microbiology (Immunology)
University Of Washington - School Of Medicine
Mini-Mba, Biopharmaceutical Innovation
Rutgers University
FAQ
Frequently asked questions about Seng-Lai "Thomas" Tan, Ph.D.
Quick answers generated from the profile data available on this page.
What company does Seng-Lai "Thomas" Tan, Ph.D. work for?
Seng-Lai "Thomas" Tan, Ph.D. works for TFC Therapeutics.
What is Seng-Lai "Thomas" Tan, Ph.D.'s role at TFC Therapeutics?
Seng-Lai "Thomas" Tan, Ph.D. is listed as Drug Hunter/Developer, Biotech Executive and Chief Scientific Officer at TFC Therapeutics.
Where is Seng-Lai "Thomas" Tan, Ph.D. based?
Seng-Lai "Thomas" Tan, Ph.D. is based in Cambridge, Massachusetts, United States while working with TFC Therapeutics.
What companies has Seng-Lai "Thomas" Tan, Ph.D. worked for?
Seng-Lai "Thomas" Tan, Ph.D. has worked for Tfc Therapeutics, Frontiers In Immunology, Bicara Therapeutics, Self-Employed, and Immunitas Therapeutics.
How can I contact Seng-Lai "Thomas" Tan, Ph.D.?
You can use AeroLeads to view verified contact signals for Seng-Lai "Thomas" Tan, Ph.D. at TFC Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Seng-Lai "Thomas" Tan, Ph.D. attend?
Seng-Lai "Thomas" Tan, Ph.D. holds Ph.D., Microbiology (Immunology) from University Of Washington - School Of Medicine.
What skills is Seng-Lai "Thomas" Tan, Ph.D. known for?
Seng-Lai "Thomas" Tan, Ph.D. is listed with skills including Drug Discovery, Immunology, Drug Development, Biomarkers, Assay Development, Biotechnology, Clinical Development, and Oncology.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial